Navigation Links
GlaxoSmithKline Recognizes University of Michigan's Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
Date:8/19/2007

New Award and Fellowship Supported by Multi-Year $1.3 Million Grant to the

ASCO Foundation

PHILADELPHIA, Aug. 16 /PRNewswire/ -- Daniel F. Hayes, MD, a University of Michigan oncologist and cancer researcher whose work in clinical and laboratory studies has advanced the management of breast cancer worldwide, was named today as the first winner of the annual Gianni Bonadonna Breast Cancer Award. Supported by a multi-year grant of more than $1.3 million from GlaxoSmithKline Oncology (GSK), the award will be presented by the American Society of Clinical Oncology (ASCO) and The ASCO Foundation at the Breast Cancer Symposium in San Francisco on September 7, 2007.

"GSK is honored to sponsor this award which is being presented to Dr. Daniel Hayes, a dedicated researcher who has been at the forefront of individualized breast cancer therapy," said Paolo Paoletti, MD, Senior Vice President of the Oncology Medicine Development Center at GlaxoSmithKline. "His contributions to the field of oncology have had an important impact on our knowledge about monitoring and managing the disease, and his findings have translated into real-world benefits for patients."

Dr. Hayes, who is Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, is a widely recognized expert in breast cancer clinical research, particularly with new hormonal and chemotherapeutic treatments. He and his colleagues published the first reports on the CA15-3 blood test, currently used worldwide to evaluate breast cancer patients. Dr. Hayes' more recent research focuses on pharmacogenomics, and understanding the key role genes play in chemotherapy treatment.

The new award and an accompanying fellowship were created in honor of one of the giants of modern-day medical oncology, Dr. Gianni Bonadonna, of the Instituto Nazionale Tumori in Milan, Italy. Dr. Bonadonna was responsible for ground-breaking research i
'/>"/>

SOURCE GlaxoSmithKline

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. GenTel acquires GlaxoSmithKline chip platform
2. Fermentation Cell Culture: University Style
3. Fueling our economy with the University of Wisconsin
4. CIO Leadership Series: Ed Meachen, University of Wisconsin System
5. University, business leaders convene in Wausau
6. University of South Florida expands GE Healthcare relationship
7. State and university form network for entrepreneurial outreach
8. University center offers speed boost to manufacturers
9. Building the modern public-purpose university should be UW Systems goal
10. University Research Park to add 20 incubator suites
11. University Research Park forms ties with German tech center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... LANSING, Mich. , March 27, 2015  Neogen ... Properties, LLC, has adopted a prearranged trading plan in ... James Herbert , Chairman and CEO of Neogen Corporation, ... shares of Neogen Corporation common stock. Herbert ... the disclosure was appropriate. The filing is only for ...
(Date:3/27/2015)... , March 27, 2015  CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... and 12 months ended December 31, 2014.  ... million), or ($0.05) per share, for the three months ...
(Date:3/26/2015)... The Market Element LLC, a leading inbound ... Designing Gig LLC to provide website design, development, and ... this alliance with Designing Gig represents a pivotal moment ... comprehensive, end-to-end, digital solution for our clients, which now ... Miller, president of The Market Element. “For small and ...
(Date:3/26/2015)... 26, 2015 ReliantHeart, Inc., an innovative ... a supplier of precision transit-time flow measurement solutions, are ... improve the efficiency of the HeartAssist5® Left ... to experience greater mobility and peace of mind. ... flow board, will draw 1/6th of the power required ...
Breaking Biology Technology:Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... 4 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin ... company in the People,s Republic,of China, today announced ... its common stock which will begin trading under ... Genesis, common stock will no longer trade,under the ...
... Shandong, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ --,China Biologic ... Biologic",or the "Company"), one of the leading ... China (the "PRC"), today announced that on,August ... Drug Administration (the "SFDA"),granted China Biologic,s production ...
... EDMONTON, Sept. 4 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today,announced that the Food and ... fast track designation for the Company,s lead drug, ... (SPMS). Dirucotide,(MBP8298) is currently being evaluated in a ...
Cached Biology Technology:Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 2Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 3China Biologic's Production Facility Renews GMP Certification 2China Biologic's Production Facility Renews GMP Certification 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 2BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 4
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... and Shenzhen, China, September 30, 2013 - China,s genomics ... the initiation of a joint project to unravel the ... of over $900k, the project will be one of ... involve experts from the IPATIMUP, a leading cancer research ...
... Pace recognizes that we are at a critical time in ... decrease in new HIV infections worldwide and increasing numbers of ... and vaccine research and new evidence on Treatment as Prevention, ... Sharon Lewin, Local Co-Chair of AIDS 2014, Head of the ...
... the human body, particularly neuroproteins that maintain proper brain ... and Parkinson,s are known as "tangle diseases" because they ... in the brain. A team of Australian and ... BMAA can be inserted into neuroproteins, causing them to ...
Cached Biology News:New mechanism for protein misfolding may link to ALS 2
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Request Info...
Candida (IgG) -Ab EIA Sample Size: 5 l...
... (Competitive) EIA Principle: The Oxidized LDL ... 4E6. Oxidized LDL in the sample competes with ... the microtiter well for the binding of the ... Sample Size: 25 l The Oxidized ...
Biology Products: